Hepatitis C News and Research

Latest Hepatitis C News and Research

Interferon linked with increased risk of depression in HCV patients

There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression.

2 May 2012

Some public health advocates disagree with Indian government's decision to roll out pentavalent vaccines, IPS reports

"Ignoring widespread concern over the safety, efficacy and cost of pentavalent vaccines" -- which provide protection against diphtheria, pertussis, tetanus, hepatitis B and haemophilus influenza type b (Hib) -- "India's central health ministry has, this month, approved inclusion of the prophylactic cocktail in the universal immunization program in seven of its provinces," Inter Press Service reports.

30 Apr 2012

Individuals with positive family history of liver cancer more likely to develop HCC

A family history of liver cancer is reported to increase risk of developing hepatocellular carcinomas (HCC), independent of hepatitis according to findings published in the May issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. The study also shows 70-fold elevated risk of HCC in those with liver cancer in the family and markers for hepatitis B (HBV) or hepatitis C.

25 Apr 2012

Severe fibrosis increases early atherosclerosis risk in patients with chronic HCV-1 infection

Italian researchers report that severe fibrosis increases the early atherosclerosis risk in patients with genotype 1 chronic hepatitis C virus (HCV) infection. A second study found that fatty liver disease also increases risk of developing atherosclerosis at an earlier period. Both studies appear in the May issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

25 Apr 2012

Crucell, ARTES enter research collaboration to develop two vaccines

ARTES Biotechnology, specialized in recombinant protein production and process development in microbial expression systems, started a development collaboration for two vaccines together with global biopharmaceutical company Crucell. Crucell is focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide.

25 Apr 2012

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.

23 Apr 2012

Sequana Medical's ALFApump System safe and effective in managing ascites

Sequana Medical announced that initial results from the PIONEER Clinical Study of its ALFApump System were presented today at the 47th annual European Association for Study of the Liver Meeting in Barcelona.

21 Apr 2012

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data from a descriptive sub-analysis of patients with compensated liver cirrhosis show that up to 43 percent of genotype-1a (GT1a) and up to 71 percent of GT1b hepatitis C virus (HCV) patients achieved sustained viral response (SVR12). SVR12 has been highly correlated with SVR24, which is a recognized indicator of viral cure.

20 Apr 2012

New data provides hope for HCV non-responders

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.

20 Apr 2012

New data shows consolidation of interferon-free revolution in HCV treatment

New data presented at the International Liver Congress 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials confirm that combinations of antivirals offer the hope of shorter, more effective treatment with fewer side effects.

20 Apr 2012

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.

20 Apr 2012

Entire HCV lifecycle can be recapitulated in murine cells

A US study presented today at The International Liver CongressTM 2012 demonstrates that the entire HCV lifecycle can be recapitulated in murine cells, implying that HCV permissive mouse models could soon be developed.

20 Apr 2012

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.

20 Apr 2012

NALFD patients with modest alcohol intake are half as likely to develop NASH

People with nonalcoholic fatty liver disease (NALFD) who consume alcohol in modest amounts - no more than one or two servings per day - are half as likely to develop hepatitis as non-drinkers with the same condition, reports a national team of scientists led by researchers at the University of California, San Diego School of Medicine.

20 Apr 2012

Childhood obesity positively associated with HCC in adulthood

Childhood obesity is a widespread global epidemic and in parallel with non-alcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease among children. New data presented today at the International Liver Congress- 2012 furthers this concern by showing that childhood obesity is positively linked with developing hepatocellular carcinoma (HCC) - the most common form of liver cancer - in adulthood.

19 Apr 2012

EASL publishes new clinical practice guideline on ALD

EASL today announced the publication of a new clinical practice guideline (CPG) in the area of Alcoholic Liver Disease (ALD), bringing the number of CPGs published to date to eight.

19 Apr 2012

Two studies show true impact of liver disease across Europe

Two studies presented at the International Liver Congress- 2012 show the true impact that liver disease has across Europe. One highlights the financial cost of liver disease to the community and the second highlights the high mortality rates associated with cirrhosis.

19 Apr 2012

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy.

19 Apr 2012

Bristol-Myers Squibb, Janssen expand TMC435, BMS-986094 clinical collaboration agreement

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Janssen R&D Ireland has broadened its clinical collaboration agreement with Bristol-Myers Squibb Company.

19 Apr 2012

Results from Presidio’s PPI-668 Phase 1a-1b trial on chronic HCV

Presidio Pharmaceuticals, Inc. announced results today from a Phase 1a-1b clinical trial of PPI-668, a potent, pan-genotypic HCV NS5A inhibitor being developed for the treatment of patients with chronic hepatitis C.

19 Apr 2012

Hepatitis C News and Research

Latest Hepatitis C News and Research

Interferon linked with increased risk of depression in HCV patients

Some public health advocates disagree with Indian government's decision to roll out pentavalent vaccines, IPS reports

Individuals with positive family history of liver cancer more likely to develop HCC

Severe fibrosis increases early atherosclerosis risk in patients with chronic HCV-1 infection

Crucell, ARTES enter research collaboration to develop two vaccines

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

Sequana Medical's ALFApump System safe and effective in managing ascites

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data provides hope for HCV non-responders

New data shows consolidation of interferon-free revolution in HCV treatment

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Entire HCV lifecycle can be recapitulated in murine cells

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

NALFD patients with modest alcohol intake are half as likely to develop NASH

Childhood obesity positively associated with HCC in adulthood

EASL publishes new clinical practice guideline on ALD

Two studies show true impact of liver disease across Europe

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Bristol-Myers Squibb, Janssen expand TMC435, BMS-986094 clinical collaboration agreement

Results from Presidio’s PPI-668 Phase 1a-1b trial on chronic HCV

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in